Broadly neutralizing antibodies (bnAbs) are currently under investigation as a therapy for HIV-1 infection and recent clinical trials have shown prolonged viral suppression by bnAbs during antiretroviral treatment interruption. Interestingly, these bnAbs also showed the ability to activate the host immune system to clear HIV-1 infected cells. There are many possibilities to further increase the potential efficacy of bnAbs. Most notably, Fc domain engineering to improve half-life and increase engagement of effector cells will augment two advantages of bnAbs. Moreover, antibody engineering can improve affinity and recognition of conserved epitopes and allows the combination of multiple epitope specificities in a single molecule. These increasingly potent and broad antibodies may prove valuable as alternative HIV-1 therapeutic and possibly in curative approaches.

目前正在研究广泛中和抗体（bnAbs）作为治疗HIV-1感染的方法，最近的临床试验表明，bnAbs在抗逆转录病毒治疗中断期间可长期抑制病毒。有趣的是，这些bnAbs还具有激活宿主免疫系统清除HIV-1感染细胞的能力。有许多可能性可以进一步提高bnAb的潜在功效。最值得注意的是，Fc结构域工程设计可改善半衰期并增加效应细胞的结合，从而增强bnAb的两个优势。而且，抗体工程可以改善亲和力和对保守表位的识别，并允许在单个分子中组合多个表位特异性。